𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer

✍ Scribed by John Eklund; Mark Kozloff; Joy Vlamakis; Alexander Starr; Margaret Mariott; Lilia Gallot; Borko Jovanovic; Lawrence Schilder; Erwin Robin; Michael Pins; Raymond C. Bergan

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
111 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Docetaxel and ketoconazole in advanced h
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma : A phase I and pharmacokinetic study
✍ Peter J. Van Veldhuizen; Gregory Reed; Arvind Aggarwal; Joaquina Baranda; Muhamm πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract ## BACKGROUND Docetaxel has significant single‐agent activity in patients with prostate carcinoma, and ketoconazole has activity as a second‐line hormonal agent. In vitro, ketoconazole exhibits synergy with several chemotherapeutic agents. A potential drug interaction exists, however,

Activity of second-line chemotherapy in
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 147 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi

A phase II study of recombinant human al
A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer
✍ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 306 KB πŸ‘ 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas